Amphastar Pharmaceuticals Income from Continuous Operations 2012-2024 | AMPH

Amphastar Pharmaceuticals income from continuous operations from 2012 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Amphastar Pharmaceuticals Annual Income from Continuous Operations
(Millions of US $)
2023 $138
2022 $91
2021 $63
2020 $1
2019 $47
2018 $-7
2017 $4
2016 $10
2015 $-3
2014 $-11
2013 $12
2012 $18
2011 $8
2009 $23
Amphastar Pharmaceuticals Quarterly Income from Continuous Operations
(Millions of US $)
2024-09-30 $40
2024-06-30 $38
2024-03-31 $43
2023-12-31 $36
2023-09-30 $49
2023-06-30 $26
2023-03-31 $26
2022-12-31 $34
2022-09-30 $16
2022-06-30 $17
2022-03-31 $24
2021-12-31 $20
2021-09-30 $31
2021-06-30 $9
2021-03-31 $4
2020-12-31 $-6
2020-09-30 $5
2020-06-30 $-1
2020-03-31 $4
2019-12-31 $1
2019-09-30 $1
2019-06-30 $47
2019-03-31 $-2
2018-12-31 $2
2018-09-30 $2
2018-06-30 $-3
2018-03-31 $-7
2017-12-31 $1
2017-09-30 $0
2017-06-30 $2
2017-03-31 $1
2016-12-31 $-3
2016-09-30 $4
2016-06-30 $7
2016-03-31 $2
2015-12-31 $8
2015-09-30 $-3
2015-06-30 $-7
2015-03-31 $-1
2014-12-31 $-3
2014-09-30 $-5
2014-06-30 $-1
2014-03-31 $-2
2013-12-31 $2
2013-09-30 $-0
2013-06-30 $8
2013-03-31 $2
2012-12-31 $4
2012-09-30 $3
2012-06-30 $5
2012-03-31 $6
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.294B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00